In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From Eisai Co., Ltd.

Medicare Spending Forecast For Leqembi Reflects CMS Angst About Alzheimer’s Drug Costs

The agency’s projection that Medicare will spend $3.5bn on Leqembi in 2025 is nearly three times the level of sales that marketer Eisai is expecting for the drug in North and South America combined in its fiscal year 2026.

Reimbursement Medicare

AACR: Akeso’s Cadonilimab Shows 1L Potential In Adenocarcinoma

With a clinical win in the Phase III COMPASSION-15 trial in gastric/gastroesophageal junction adenocarcinoma, Akeso's PD-1/CTLA-4-targeting agent is well positioned to expand its label beyond second- or third-line use for cervical cancer, and appears to stack up well against big global competitors. The Chinese firm is also aiming the bispecific antibody at hepatocellular and lung cancers.

China Clinical Trials

Deal Watch: Gilead Acquires Xilio’s IL-12 Activating Candidate

Plus deals involving Avalo/AlmataBio, AbbVie/Parvus, NovaBay/Eyenovia, Bayer/Aignostics, Merck & Co./Pearl, tech transfer agreements and deals in brief.

Deal Watch Business Strategies

Leqembi’s EU Approval Process Delayed Over Advisory Group COI Considerations

The EU regulatory agency’s discussions for lecanemab’s approval are hit by a decision to annul advice from an advisory committee due to the implications of a Court of Justice ruling on the handling of experts' competing interests.

Europe Drug Review
See All

Company Information

  • Industry
  • Distributors
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • EA Pharma Co., Ltd.
    • Eisai China Inc
    • Eisai Laboratorios
    • Eisai Mexico
    • Eisai Participacoes Ltda. (Brazil Subsidiary)
    • H3 Biomedicine
    • HI-Eisai Pharmaceutical Inc.
    • Jingyi Weixiang (Shanghai) Health Industry Development Limited
    • Liaoning TianYi Biological Pharmaceutical Co., Ltd.
    • KAN Research Institute, Inc.
    • MGI Pharma, Inc.
    • Morphotek, Inc.
    • Zycos Inc.
    • Eisai Vietnam Co., Ltd.
UsernamePublicRestriction

Register